Calidi Biotherapeutics (Nevada), Inc.

Overview

• HeadquartersNV¹
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

Calidi Biotherapeutics (Nevada), Inc. is part of a group headed by Calidi Biotherapeutics, Inc.. 6 entities, 4 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (1 companies). Each entity in the chart links to its source.

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive Officer, DirectorAllan Camaisa named Jun 29, 2023²
• Vice President of Technical OperationsAmish F. Patel named Jun 29, 2023²
• Senior Vice President, Global Head of Research and DevelopmentAnthony F. Santidrian named Jun 29, 2023²
• Interim Chief Medical OfficerBoris Minev named Jun 29, 2023²
• Chief of Corporate DevelopmentDavid F. Sans named Jun 29, 2023²
• Chief Business OfficerStephen Thesing named Jun 29, 2023²
• Interim Chief Financial OfficerTony Kalajian named Jun 29, 2023²
• Chief Administrative Officer, Chief Legal Officer, Chief Diversity OfficerWendy Pizarro named Jun 29, 2023²
• DirectorAlfonso F. Zulueta named Jun 29, 2023²
• DirectorGeorge Ng named Jun 29, 2023²
• DirectorHeehyoung F. Lee named Jun 29, 2023²
• DirectorJames F. Schoeneck named Jun 29, 2023²
• DirectorScott F. Leftwich named Jun 29, 2023²

Filings

5 filings to the SEC since October 2021: 1 private raises, 4 other. The latest 5:

1. Jun 29, 2023D EDGAR
2. Aug 2, 2022425 EDGAR
3. Jun 28, 2022425 EDGAR
4. May 24, 2022425 EDGAR
5. May 24, 2022425 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Stakes it holds

Calidi Biotherapeutics (Nevada), Inc. has told the SEC it owns more than 5% of 1 company, latest first (Schedules 13D and 13G).

• Bank of MontrealSC 13G/A Feb 9, 2024³

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Jun 20, 2023Raised $5 million in a private offering of equity² Form D: $25 million offered in all Form D